Abstract
Psoriatic arthritis is an inflammatory and possibly destructive form of arthritis. As in rheumatoid arthritis and ankylosing spondylitis, the use of biological therapy in psoriatic arthritis is a therapeutic revolution: both articular and cutaneous efficacy have been shown, and some improvement is visible on radiography. The benefit-risk ratio will improve when we learn to identify more accurately the patients likely to benefit from these treatments.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adalimumab
-
Algorithms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Psoriatic / diagnosis
-
Arthritis, Psoriatic / drug therapy*
-
Dermatologic Agents / administration & dosage
-
Dermatologic Agents / therapeutic use*
-
Etanercept
-
Forecasting
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / therapeutic use*
-
Infliximab
-
Multicenter Studies as Topic
-
Randomized Controlled Trials as Topic
-
Receptors, Tumor Necrosis Factor / administration & dosage
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Risk Assessment
-
Severity of Illness Index
-
Time Factors
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Dermatologic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Adalimumab
-
Etanercept